Greenwich Lifesciences Net Income From Continuing Ops Over Time
| GLSI Stock | USD 29.00 3.81 15.13% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Greenwich Lifesciences Performance and Greenwich Lifesciences Correlation. Greenwich | Build AI portfolio with Greenwich Stock |
Is there potential for Biotechnology market expansion? Will Greenwich introduce new products? Factors like these will boost the valuation of Greenwich Lifesciences. Market participants price Greenwich higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Greenwich Lifesciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Greenwich Lifesciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Greenwich Lifesciences' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Greenwich Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Greenwich Lifesciences and related stocks such as Cognition Therapeutics, Atossa Genetics, and Tevogen Bio Holdings Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGTX | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (4.8 M) | (7.8 M) | (11.7 M) | (43.6 M) | (22.8 M) | (34 M) | (30.6 M) | (32.1 M) |
| ATOS | (5.1 M) | (5.1 M) | (5.1 M) | (10.8 M) | (14.7 M) | (12.8 M) | (6.4 M) | (8.1 M) | (11.4 M) | (17.2 M) | (17.8 M) | (20.6 M) | (27 M) | (29.8 M) | (25.5 M) | (23 M) | (24.1 M) |
| TVGN | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 4.4 M | (67.3 K) | (13.7 M) | (15.8 M) | (15 M) |
| ONCY | 0.0 | 0.0 | 0.0 | 0.0 | (16 M) | (5.2 M) | (15.1 M) | (15.6 M) | (17 M) | (33.1 M) | (22.5 M) | (26.3 M) | (24.8 M) | (32.4 M) | (31.7 M) | (28.5 M) | (27.1 M) |
| SRZN | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (32.7 M) | (54.6 M) | (36 M) | (34.9 M) | (63.6 M) | (57.2 M) | (60.1 M) |
| HURA | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (9.4 M) | (29.3 M) | (21.7 M) | (19.5 M) | (20.5 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (91 M) | (86.6 M) | (77.9 M) | (81.8 M) |
| IRD | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| AGEN | (23.3 M) | (23.3 M) | (11.3 M) | (30.1 M) | (42.7 M) | (88.1 M) | (127.1 M) | (120.7 M) | (162 M) | (111.6 M) | (182.9 M) | (28.7 M) | (228.7 M) | (283 M) | (232.3 M) | (209 M) | (198.6 M) |
| IMMX | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (972.8 K) | (1.1 M) | (24.4 M) | (8.2 M) | (14.2 M) | (21.7 M) | (19.5 M) | (18.6 M) |
Greenwich Lifesciences and related stocks such as Cognition Therapeutics, Atossa Genetics, and Tevogen Bio Holdings Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Greenwich Lifesciences | GLSI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Building 14, Stafford, |
| Exchange | NASDAQ Exchange |
USD 29.0
Check out Greenwich Lifesciences Performance and Greenwich Lifesciences Correlation. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Greenwich Lifesciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.